Alzheimer's disease vaccine - BELLUS Health
Latest Information Update: 03 Jul 2023
At a glance
- Originator Neurochem
- Developer BELLUS Health; National Research Council Canada
- Class Alzheimer vaccines; Antidementias; Neuroprotectants
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease